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OBJECTIVES The purpose of this study was to determine the mechanisms of sudden death (SD) in patients
with ventricular tachyarrhythmias (ventricular tachycardia/ventricular fibrillation [VT/VF])
treated with an implantable cardioverter defibrillator (ICD).
BACKGROUND Despite ICD therapy, some patients with VT/VF still die suddenly. Optimal ICD use
requires determination of the mechanisms of these residual SDs.
METHODS We reviewed 320 patient deaths during trials of Medtronic transvenous ICD systems
(Medtronic Inc., Minneapolis, Minnesota). Sudden deaths were further categorized accord-
ing to mechanism. Post-shock electromechanical dissociation (EMD) describes a scenario
where VT/VF was appropriately detected and treated by an ICD shock that restored a
physiologic rhythm, but death still occurred immediately by EMD.
RESULTS A mode of death could be ascribed for 317 patients—90 (28%) were sudden, 156 (49%) were
nonsudden cardiac, and 71 (22%) were noncardiac. A mechanism of SD was proposed for 68
patients—20 (29%) had post-shock EMD, 17 (25%) had VT/VF uncorrected by shocks, 11
(16%) had primary electromechanical dissociation, 9 (13%) had incessant VT/VF, 5 (7%) had
VT/VF after their ICD was deactivated or removed, and 6 (9%) had single instances of
various other terminal events. Only New York Heart Association functional class indepen-
dently predicted SD by post-shock EMD.
CONCLUSIONS The most common mechanism of SD in patients with an ICD is VT/VF treated with
an appropriate shock followed by EMD. As this mechanism accounted for 29% of the
SDs to which a cause could be ascribed, this mechanism of SD warrants further
investigation. (J Am Coll Cardiol 2002;39:1323–8) © 2002 by the American College of
Cardiology Foundation
Patients who have had sustained ventricular tachycardia/
ventricular fibrillation (VT/VF) without a transient or
reversible cause are at high risk of VT/VF recurrence and
sudden death (SD) (1–3). Of the therapeutics proposed for
these patients, the implantable cardioverter defibrillator
(ICD) best prevents follow-up mortality (4–6). Neverthe-
less, SDs still occur in patients with an ICD (7–39).
Accordingly, optimal use of ICD therapy requires determi-
nation of the mechanisms of these residual SDs.
The goal of this study was to determine the mechanisms
of death of patients with a non-thoracotomy ICD, with
emphasis on the mechanisms of SD (40).
METHODS
Data were obtained from the events committee review of
ICD patient deaths during pre-clinical studies of Medtronic
non-thoracotomy ICDs (Medtronic Inc., Minneapolis,
Minnesota) from 1994 to 1999. Each patient provided
consent for this review. The events committee accessed,
whenever possible, descriptions of the terminal event by the
patient’s family, paramedic and emergency room reports,
clinical summaries by attending physicians, physician/
nursing progress notes, death certificates and post-mortem
interrogation of the ICD memory logs. Deaths were first
classified as sudden or nonsudden using definitions summa-
rized below. Nonsudden deaths were further classified as
cardiac or noncardiac. Finally, a specific cause was ascribed.
Definitions. Definitions proposed by the North American
Society of Pacing and Electrophysiology policy conference
(40) on standardized reporting of ICD patient outcomes
were used. Sudden death was defined as that occurring
within 1 h of onset of symptoms or unexpected and
unwitnessed death during sleep. Nonsudden cardiac deaths
were those with a central cardiac cause that were not
sudden. Other deaths were noncardiac deaths.
Sudden deaths that began with VT/VF were further
subgrouped. A detection failure death was that secondary to
VT/VF with rates within the detection zones of the ICD
that did not evoke an ICD response. A shock failure death
was that due to VT/VF appropriately treated by the ICD
with its full complement of shocks (four to six depending on
From the *Foothills Hospital/University of Calgary, Calgary, Alberta, Canada;
†Cardiac Surgical Associates, Minneapolis, Minnesota; ‡Jesse E. Edwards Registry of
Cardiovascular Disease of United Hospital, St. Paul, Minnesota; §Medtronic Inc.,
Minneapolis, Minnesota; and University of Minnesota, Minneapolis, Minnesota.
Supported by Medtronic Inc., Minneapolis, Minnesota.
Manuscript received January 30, 2001; revised manuscript received January 7, 2002,
accepted January 18, 2002.
Journal of the American College of Cardiology Vol. 39, No. 8, 2002
© 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(02)01784-9
the ICD model) without terminating VT/VF. A redetection
failure death was that due to VT/VF appropriately treated
by the ICD with less than its full complement of therapies
with persistence of VT/VF that was not recognized by the
device. Incessant VT/VF was that appropriately detected
and effectively treated by the ICD but which immediately
recurred over and over to death. Post-shock electromechan-
ical dissociation (EMD) describes a scenario where VT/VF
was appropriately detected and effectively treated by four or
less ICD shocks that restored a cardiac rhythm with the
physiologic rate (40 to 150 beats/min) but that was then
immediately followed by EMD and death.
Statistical analysis. Continuous data are presented as
mean  1 SD and were compared using Student t test.
Categorical data are presented as ratios (%) and were
compared using the chi-square statistic. Independent pre-
dictors of post-shock EMD were sought using logistic
regression analysis. A two-tailed p value of 0.05 was used
to exclude the null hypothesis.
RESULTS
Study population. From 1994 to 1999, 4,889 patients
participated in pre-clinical trials of Medtronic non-
thoracotomy ICDs (models 7219, 7220, 7221, 7223, 7250
and 7273) in Canada and the U.S. and were followed for a
total of 2,971 patient-years. During that time, 320 deaths
occurred in 257 men and 63 women of mean age 68  11
years with a mean New York Heart Association (NYHA)
class of 2.4  0.8 and a mean left ventricular ejection
fraction (LVEF) of 0.27  0.13. Their structural heart
disease was coronary artery disease in 274 (86%), congestive
cardiomyopathy in 26 (8%), hypertrophic cardiomyopathy
in 7 (2%), valvular heart disease in 7 (2%), congenital
long-QT interval syndrome in 2 (0.6%) and amyloid heart
disease in 1 (0.3%). Three (1%) patients had no structural
heart disease.
Modes of death. Three (1%) deaths could not be classified,
because no other information was available. Of the remain-
ing 317 deaths, 90 (28%) were sudden, 156 (49%) were
nonsudden cardiac, and 71 (22%) were noncardiac.
Compared with patients with nonsudden cardiac or
noncardiac deaths, patients with SD were younger and
tended to have more coronary artery disease and less
nonischemic congestive cardiomyopathy (Table 1). Patients
with nonsudden cardiac death were more likely to be in
NYHA class III/IV and to have a low LVEF than patients
with SD who, in turn, were more likely to be in NYHA
III/IV and to have a low LVEF than patients with noncar-
diac death. Patients with SD were less likely to die in a
hospital or a hospice than were patients with nonsudden
cardiac or noncardiac death (Table 2). Patients with non-
sudden cardiac death were most likely and patients with
noncardiac death were least likely to have an appropriate
ICD therapy during follow-up. Patients with SD were more
likely to have died with an active ICD and to have that ICD
interrogated after death. Finally, patients with nonsudden
cardiac death were more likely to be receiving an anti-
arrhythmic drug at the time of death. There were no
significant differences in the prevalence of beta-adrenergic
blocking agent drug use.
Mechanisms of death. Of the 71 patients with noncardiac
death, the cause was respiratory in 20 (28%), sepsis in 16
(22%), gastrointestinal in 10 (14%), carcinoma in 9 (13%),
cerebrovascular in 7 (10%), renal in 5 (7%), other vascular
(two dissecting abdominal aortic aneurysms and one pul-
monary embolus) in 3 (4%) and trauma in 1 (1%) patient.
The most common cause of nonsudden cardiac death was
progressive heart failure—129 (83%) of 156 patients. An
additional 17 (11%) died of nonsudden consequences of
VT/VF, 3 (2%) died of the nonsudden consequences of
EMD, 3 (2%) died as a consequence of cardiac transplan-
tation, 2 (2%) died of infective endocarditis, 1 (1%) died of
cardiac tamponade, and 1 (1%) died as a consequence of
coronary artery bypass grafting.
Of the 90 SDs, the probable mechanism of death could
Abbreviations and Acronyms
ED50  the median effective shock dose
EMD  electromechanical dissociation
ICD  implantable cardioverter defibrillator
LD50  the medial lethal shock dose
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
SD  sudden death
TD50  the median toxic shock dose
VF  ventricular fibrillation
VT  ventricular tachycardia
Table 1. Patient Characteristics (Before ICD Implantation) by Mode of Death
Attribute n All Deaths Sudden Deaths Nonsudden Cardiac Noncardiac Deaths p Value
Age (yrs) 317 67.8  11.0 64.8  11.0 69.2  10.3 68.8  12.1 0.008
Men 317 80% 83% 78% 82% NS
CAD (%) 317 85% 92% 83% 83% 0.098
CCM (%) 317 8% 3% 12% 7% 0.07
Class III/IV (%) 303 43% 39% 53% 24%  0.001
LVEF 281 0.27  0.13 0.27  0.15 0.24  0.10 0.33  0.15  0.001
CAD  coronary artery disease with or without prior myocardial infarction; CCM  nonischemic cardiomyopathy; Class III/IV  New York Heart Association heart failure
function class III or IV; ICD  implantable cardioverter defibrillator; LVEF  left ventricular ejection fraction; n  number of patients with complete data; p value  statistical
significance level by either analysis of variance or contingency table chi-square analysis, as appropriate.
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be determined in 68 (76%) (Fig. 1). Only 13 (19%) of the 68
adjudicated SDs did not involve VT/VF—11 from primary
EMD, 1 from a primary bradyarrhythmia and 1 from status
asthmaticus. The other 55 (81%) of the 68 adjudicated SDs
involved VT/VF. In five (9%) of these 55 patients, the ICD
had been deactivated or removed. Otherwise, no instances
of ICD failure to initially detect VT/VF were recognized.
However, one patient experienced redetection failure. Fail-
ure to terminate VT/VF with all ICD therapies occurred in
17 cases (34% of SDs due to VT/VF in patients with a
functioning ICD). Incessantly recurrent VT/VF occurred in
nine cases (18% of SDs due to VT/VF in patients with a
functioning ICD). One patient died of untreated VT with a
rate below the programmed ICD detection zone, one died
after conversion of supraventricular tachycardia to VT/VF
by the ICD, and one died due to a motor vehicle accident
precipitated by successfully treated VT/VF. Nevertheless,
most SDs due to VT/VF in patients with a functioning
ICD were due to post-shock EMD—20 cases (29% of the
68 SDs to which a mechanism was ascribed, 36% of the 55
SDs due to VT/VF, and 40% of the 50 SDs due to VT/VF
in patients with a functioning ICD).
Table 2. Patient Characteristics (After ICD Implantation) by Mode of Death
Attribute n All Deaths Sudden Deaths Nonsudden Cardiac Noncardiac Deaths p Value
LED (Js) 306 14.6  16.8 15.1  6.8 14.8  6.9 13.4  6.5 NS
Follow-up (days) 317 143  133 135  128 152  134 137  124 NS
OP-MORT (%) 317 17% 18% 16% 17% NS
In-hosp (%) 317 70% 29% 88% 80%  0.001
ICD Rx (%) 317 55% 54% 63% 39% 0.005
ICD ON (%) 317 75% 94% 68% 66%  0.001
ICD INTERRO (%) 238 44% 54% 42% 32% 0.036
AA (%) 312 51% 41% 60% 41% 0.005
Beta-blocker (%) 317 16% 20% 13% 17% NS
AA  antiarrhythmic drug therapy at time of death; Beta-blocker  beta-blocker drug therapy at time of death; ICD  implantable cardioverter defibrillator; ICD ON  ICD
active at time of death; ICD Rx  appropriate ICD therapy supplied before terminal event; ICD INTERRO  post-mortem ICD interrogation performed (of those ICDs that
were active at time of death); In-hosp  after admission to a hospital or hospice; LED  lowest intra-operative energy of successful defibrillation; n  number of patients with
complete data; OP-MORT  percentage of deaths that were in the operative period; p value  statistical significance level by either analysis of variance or contingency table
chi-square analysis, as appropriate.
Figure 1. Frequency distribution pie chart for adjudicated mechanisms of SD of 68 consecutive patients with a non-thoracotomy implantable cardioverter
defibrillator (ICD) during pre-clinical device evaluation. The portion labeled VT/VF-OTHER includes one each of conversion of supraventricular
tachyarrhythmia to ventricular fibrillation (VF), untreated ventricular tachycardia (VT) (as programmed), failure to redetect VT/VF after a shock therapy
and trauma from a motor vehicle accident secondary to treated VT/VF. EMD  electromechanical dissociation.
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Post-shock EMD. Post-shock EMD followed one shock
in eight patients, two shocks in five patients, three shocks in
four patients and four shocks in three patients. The mean
magnitude of the final shock was 31.0  7.8 J and was the
maximum output of the ICD in 17 patients. The post-shock
cardiac rhythm was documented in 15 patients, being
idioventricular in seven, ventricular paced in four and sinus
rhythm in four patients.
Two clinical factors were associated with post-shock
EMD—a lower LVEF and NYHA class of III/IV (Tables
3 and 4). Only the latter was an independent predictor of
post-shock EMD by logistic regression. The hazard ratio
for patients with NYHA class III/IV to experience SD by
post-shock EMD rather than by another mechanism was
2.3 (95% confidence interval: 1.15 to 4.61).
DISCUSSION
The important observations of this study are that SD is still
a common mode of death in VT/VF patients treated with
an ICD and that post-shock EMD is the most common
mechanism of SD in these patients. Finally, post-shock
EMD is associated with high-energy shocks in patients with
advanced congestive heart failure.
Previous studies—modes of deaths in ICD patients. The
distribution of modes of death reported in the present study
are in general agreement with those previously reported
(6–39). These reference studies reported the modes of death
of 1,576 VT/VF patients treated with an ICD—23% of the
deaths were sudden, 48% were nonsudden cardiac, and 27%
were noncardiac. In the present study, 28% of deaths were
sudden, 49% were nonsudden cardiac, and 22% were non-
cardiac.
Nineteen reference studies (6–8,10–12,16–18,21,25,26,30,
36,38,39,41–43) reported mechanisms of 71 SDs in VT/VF
patients with a functioning ICD. Thirty-three (46%) of these
SDs did not involve VT/VF—13 (18%) resulted from a
primary bradyarrhythmia, 11 (15%) resulted from primary
EMD, and 9 (13%) were due to anatomic catastrophes. The
present study noted fewer SDs due to bradyarrhythmias, likely
as a consequence of the pacing capabilities of newer ICDs. The
reference studies suggest that incessant VT/VF (26%) and
shock failure (18%) are frequent mechanisms of SD in patients
with a functioning ICD whose death involved VT/VF. The
present study supports these suggestions, albeit with reversed
frequency. As in the present study, combined experience of the
reference studies indicate that other mechanisms of SD in this
setting are rare, with the exception of post-shock EMD.
Although the reference studies have not recognized the unique
nature of post-shock EMD as a mechanism of SD, they
describe events similar to post-shock EMD in 18 (25%) of
their 71 adjudicated mechanisms of SD. The higher frequency
of post-shock EMD in the present study is likely due to its
prospective inclusion as a category of SD.
Potential mechanisms of post-shock EMD. It is possible
that post-shock EMD is an epiphenomenon arising from
some other fatal event, such as global myocardial ischemia,
that produces collateral VT/VF. Correction of this collateral
VT/VF would not prevent death. Alternatively, the VT/VF
may be the primary event. Appropriate ICD function then
replaces VT/VF with shock-induced EMD. Which of these
circumstances is operative cannot be determined from the
data of this study. Nevertheless, clinical experience,
biologically-plausible associations and previous descriptions
support the probability that many of these deaths result
from ICD shocks that are either too frequent, too closely
spaced or too large in magnitude.
Table 3. Patient Characteristics (Before ICD Implantation) by Mechanism of Death
Attribute n All Sudden Deaths Post-Shock EMD Not Post-Shock EMD p Value
Age (yrs) 68 63.7  10.8 64.4  10.3 63.4  11.0 NS
Men (%) 68 82% 85% 81% NS
CAD (%) 68 91% 90% 92% NS
CCM (%) 68 3% 5% 2% NS
Class III/IV (%) 66 36% 60% 26% 0.008
LVEF 63 28.4  15.7 22.5  9.7 30.9  17.2 0.049
p value  statistical significance level by either Student t test or chi-square analysis, as appropriate. Abbreviations as in Table 1.
Table 4. Patient Characteristics (After ICD Implantation) by Mechanism of Death
Attribute n All Sudden Deaths Post-Shock EMD Not Post-Shock EMD p Value
LED (Js) 65 15.5  7.0 17.9  7.1 14.5  6.9 0.077
Follow-up (days) 68 126  126 163  154 110  111 0.117
OP-MORT (%) 68 22% 20% 23% NS
In-hosp (%) 68 37% 30% 40% NS
ICD Rx (%) 68 50% 60% 46% NS
ICD ON (%) 68 93% 100% 90% 0.129
ICD INTERRO (%) 63 73% 85% 67% 0.140
AA (%) 66 62% 53% 66% NS
Beta-blocker (%) 66 79% 74% 81% NS
EMD  electromechanical dissociation; p value  statistical significance level by either Student t test or chi-square analysis, as
appropriate; other abbreviations as in Table 2.
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Shock induced myocardial dysfunction. Animal models
have demonstrated a vast array of potentially deleterious
consequences of DC shocks including changes in cellular
morphology (44–48), biochemical function (49), electro-
physiologic function (45,47–49) and hemodynamic func-
tion (49). Of importance, many of these functional changes
have been demonstrated to last for minutes to hours as
opposed to seconds (47–49). Furthermore, DC shocks of
high field-strengths have been shown to cause death in dogs
secondary to EMD (45,48).
These animal studies (44–49) demonstrated that dys-
function, damage and death require shock magnitudes
considerably in excess of that used clinically. Using the
pharmacologic dose-response curve approach, Babbs et al.
(46) determined the median effective shock dose (correction
of VF) (ED50), the median toxic shock dose (myocyte
necrosis) (TD50) and the medial lethal shock dose (death)
(LD50) of overdamped sine wave DC shocks in dogs.
Expressed as total energy, the ED50, TD50 and LD50 were
1.5 J/kg, 30 J/kg and 470 J/kg, respectively. The dose
response curves for defibrillation efficacy and for death did
not overlap. However, the positions of these dose response
curves in humans with heart disease may be different than
those of dogs with normal hearts.
Many of the morphologic (50), biochemical (51), elec-
trophysiologic (51) and hemodynamic (52) adverse effects of
high-intensity DC shocks reported in animals models have
also been noted, albeit with lower frequency, in patients who
have received DC shocks of clinically relevant intensities. As
in animal models, many of these functional changes have
been demonstrated to last for minutes to hours as opposed
to seconds (52).
The immediacy of post-shock EMD suggests that necro-
sis is not required for the phenomenon. Instead, it is likely
that an immediate functional abnormality is responsible.
This probability is supported by reports of severe hemody-
namic deterioration after internal DC shocks during ICD
implantation procedures (42,52). Furthermore, these in-
stances of hemodynamic deterioration were predicted by
poor left ventricular function. A severe manifestation of this
phenomenon could be expressed as SD due to EMD.
Clinical significance. The frequency of post-shock EMD
as a mechanism of SD in patients with an ICD recommends
development of preventative measures. Such measures
might include better patient selection (42,53), use of the
minimum shock strength compatible with effective defibril-
lation (54), lead systems that avoid focal myocardial con-
centration of the potential gradients of the DC shock (55),
shock waveforms that reduce the probability of myocyte
dysfunction (56), pharmacologic therapies that reduce the
occurrence of the phenomenon (57) and ICD therapies that
treat the EMD should it occur (58).
Conclusions. Review of the causes of 320 deaths in VT/VF
patients treated with an ICD revealed that 28% of these deaths
are still sudden. The most common mechanisms of these SDs
was VT/VF treated with an appropriate DC shock resulting in
EMD and death. Post-shock EMD, which we have also
termed cardiac annihilation (59), accounted for 29% of the 68
SDs to which a mechanism was ascribed, for 36% of the 55
SDs due to VT/VF and for 40% of the 50 SDs due to VT/VF
in patients with a functioning ICD in place. Recognition of
this phenomenon will prompt further investigations into its
mechanism(s). Prevention of the phenomenon should lead to
an improvement in the efficacy of ICD therapy.
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